Diversity of antinuclear antibody responses in hepatocellular carcinoma

Giovanni Covini, Carlos A. Von Mühlen, Stefania Pacchetti, Massimo Colombo, Edward K L Chan, Eng M. Tan

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background/Aims: The development of antinuclear antibodies (ANA) in malignancies has been described but its mechanism is still not understood. The aim of this Study was to examine ANA specificities in hepatocellular carcinoma to further understand autoimmunity in cancer. Methods: Two hundred and four hepatocellular carcinoma patients were compared with 68 chronic hepatitis C, with 126 chronic hepatitis B and with 30 alcoholic liver cirrhosis patients, as well as with 87 healthy donors. Indirect immunofluorescence, immunoblotting, and immunoprecipitation were used to study ANA reactivities. Results: Hepatocellular carcinoma had a significantly higher frequency of ANA using HEp-2 cells as substrate (31%) than chronic hepatitis C (10%), chronic hepatitis B (9.5%), alcoholic liver cirrhosis (10%) or healthy donors (4.5%). A great diversity of ANA specificities was found in hepatocellular carcinoma. Three hepatoma sera had antibodies that co-localized with non-snRNP splicing factor SC35, suggesting that the antigenic targets might be involved in mRNA splicing. We identified antibodies to two known nuclear autoantigens: fibrillarin and p330(d)/CENP- F. These autoantigens are involved in the 5' processing of precursor ribosomal RNA transcripts and in mitotic functions, respectively. Conclusions: Diversity was found in the autoantibody specificity, in contrast to the specific subsets of autoantibodies seen in several systemic rheumatic autoimmune disease. Our data suggest that immune response in hepatocellular carcinoma targets important proteins involved in cellular biosynthetic or proliferative functions.

Original languageEnglish
Pages (from-to)1255-1265
Number of pages11
JournalJournal of Hepatology
Volume26
Issue number6
DOIs
Publication statusPublished - Jul 1997

Fingerprint

Antinuclear Antibodies
Antibody Formation
Hepatocellular Carcinoma
Alcoholic Liver Cirrhosis
Antibody Specificity
Chronic Hepatitis B
Autoantigens
Chronic Hepatitis C
Autoantibodies
Tissue Donors
Antibodies
RNA Precursors
Indirect Fluorescent Antibody Technique
Rheumatic Diseases
Autoimmunity
Immunoprecipitation
Immunoblotting
Autoimmune Diseases
Neoplasms
Messenger RNA

Keywords

  • Antinuclear antibody
  • Autoantibody
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Diversity of antinuclear antibody responses in hepatocellular carcinoma. / Covini, Giovanni; Von Mühlen, Carlos A.; Pacchetti, Stefania; Colombo, Massimo; Chan, Edward K L; Tan, Eng M.

In: Journal of Hepatology, Vol. 26, No. 6, 07.1997, p. 1255-1265.

Research output: Contribution to journalArticle

Covini, Giovanni ; Von Mühlen, Carlos A. ; Pacchetti, Stefania ; Colombo, Massimo ; Chan, Edward K L ; Tan, Eng M. / Diversity of antinuclear antibody responses in hepatocellular carcinoma. In: Journal of Hepatology. 1997 ; Vol. 26, No. 6. pp. 1255-1265.
@article{902994e7e00842e7b08c2360e5ed9a09,
title = "Diversity of antinuclear antibody responses in hepatocellular carcinoma",
abstract = "Background/Aims: The development of antinuclear antibodies (ANA) in malignancies has been described but its mechanism is still not understood. The aim of this Study was to examine ANA specificities in hepatocellular carcinoma to further understand autoimmunity in cancer. Methods: Two hundred and four hepatocellular carcinoma patients were compared with 68 chronic hepatitis C, with 126 chronic hepatitis B and with 30 alcoholic liver cirrhosis patients, as well as with 87 healthy donors. Indirect immunofluorescence, immunoblotting, and immunoprecipitation were used to study ANA reactivities. Results: Hepatocellular carcinoma had a significantly higher frequency of ANA using HEp-2 cells as substrate (31{\%}) than chronic hepatitis C (10{\%}), chronic hepatitis B (9.5{\%}), alcoholic liver cirrhosis (10{\%}) or healthy donors (4.5{\%}). A great diversity of ANA specificities was found in hepatocellular carcinoma. Three hepatoma sera had antibodies that co-localized with non-snRNP splicing factor SC35, suggesting that the antigenic targets might be involved in mRNA splicing. We identified antibodies to two known nuclear autoantigens: fibrillarin and p330(d)/CENP- F. These autoantigens are involved in the 5' processing of precursor ribosomal RNA transcripts and in mitotic functions, respectively. Conclusions: Diversity was found in the autoantibody specificity, in contrast to the specific subsets of autoantibodies seen in several systemic rheumatic autoimmune disease. Our data suggest that immune response in hepatocellular carcinoma targets important proteins involved in cellular biosynthetic or proliferative functions.",
keywords = "Antinuclear antibody, Autoantibody, Hepatocellular carcinoma",
author = "Giovanni Covini and {Von M{\"u}hlen}, {Carlos A.} and Stefania Pacchetti and Massimo Colombo and Chan, {Edward K L} and Tan, {Eng M.}",
year = "1997",
month = "7",
doi = "10.1016/S0168-8278(97)80460-6",
language = "English",
volume = "26",
pages = "1255--1265",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Diversity of antinuclear antibody responses in hepatocellular carcinoma

AU - Covini, Giovanni

AU - Von Mühlen, Carlos A.

AU - Pacchetti, Stefania

AU - Colombo, Massimo

AU - Chan, Edward K L

AU - Tan, Eng M.

PY - 1997/7

Y1 - 1997/7

N2 - Background/Aims: The development of antinuclear antibodies (ANA) in malignancies has been described but its mechanism is still not understood. The aim of this Study was to examine ANA specificities in hepatocellular carcinoma to further understand autoimmunity in cancer. Methods: Two hundred and four hepatocellular carcinoma patients were compared with 68 chronic hepatitis C, with 126 chronic hepatitis B and with 30 alcoholic liver cirrhosis patients, as well as with 87 healthy donors. Indirect immunofluorescence, immunoblotting, and immunoprecipitation were used to study ANA reactivities. Results: Hepatocellular carcinoma had a significantly higher frequency of ANA using HEp-2 cells as substrate (31%) than chronic hepatitis C (10%), chronic hepatitis B (9.5%), alcoholic liver cirrhosis (10%) or healthy donors (4.5%). A great diversity of ANA specificities was found in hepatocellular carcinoma. Three hepatoma sera had antibodies that co-localized with non-snRNP splicing factor SC35, suggesting that the antigenic targets might be involved in mRNA splicing. We identified antibodies to two known nuclear autoantigens: fibrillarin and p330(d)/CENP- F. These autoantigens are involved in the 5' processing of precursor ribosomal RNA transcripts and in mitotic functions, respectively. Conclusions: Diversity was found in the autoantibody specificity, in contrast to the specific subsets of autoantibodies seen in several systemic rheumatic autoimmune disease. Our data suggest that immune response in hepatocellular carcinoma targets important proteins involved in cellular biosynthetic or proliferative functions.

AB - Background/Aims: The development of antinuclear antibodies (ANA) in malignancies has been described but its mechanism is still not understood. The aim of this Study was to examine ANA specificities in hepatocellular carcinoma to further understand autoimmunity in cancer. Methods: Two hundred and four hepatocellular carcinoma patients were compared with 68 chronic hepatitis C, with 126 chronic hepatitis B and with 30 alcoholic liver cirrhosis patients, as well as with 87 healthy donors. Indirect immunofluorescence, immunoblotting, and immunoprecipitation were used to study ANA reactivities. Results: Hepatocellular carcinoma had a significantly higher frequency of ANA using HEp-2 cells as substrate (31%) than chronic hepatitis C (10%), chronic hepatitis B (9.5%), alcoholic liver cirrhosis (10%) or healthy donors (4.5%). A great diversity of ANA specificities was found in hepatocellular carcinoma. Three hepatoma sera had antibodies that co-localized with non-snRNP splicing factor SC35, suggesting that the antigenic targets might be involved in mRNA splicing. We identified antibodies to two known nuclear autoantigens: fibrillarin and p330(d)/CENP- F. These autoantigens are involved in the 5' processing of precursor ribosomal RNA transcripts and in mitotic functions, respectively. Conclusions: Diversity was found in the autoantibody specificity, in contrast to the specific subsets of autoantibodies seen in several systemic rheumatic autoimmune disease. Our data suggest that immune response in hepatocellular carcinoma targets important proteins involved in cellular biosynthetic or proliferative functions.

KW - Antinuclear antibody

KW - Autoantibody

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0343471567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343471567&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(97)80460-6

DO - 10.1016/S0168-8278(97)80460-6

M3 - Article

VL - 26

SP - 1255

EP - 1265

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -